Trial reportMicrobial cell factories2015
Effective treatment of hypertension by recombinant Lactobacillus plantarum expressing angiotensin converting enzyme inhibitory peptide.
Trial report in Microbial cell factories, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 78 citations in OpenAlex.
- Pilot assessment of probiotics for pregnant women in Rwanda.PloS one · 2018Trial
- Activity Enhancement of a Truncated Lipase-Phospholipase from the Marine Thraustochytrid Aurantiochytrium Sp. MG91.Molecular biotechnology · 2026Article
- Effects and mechanisms of probiotics supplement on hypertension.Journal of hypertension · 2026Review
- Exploring the basis of Traditional Chinese Medicine in treating cardiovascular disease: insights into the microbiota-gut-heart axis.Chinese medicine · 2026Review
- Engineered probiotic ameliorates hyperlipidemia and atherosclerosis by secreting PCSK9 nanobodies and regulating gut microbiota.Bioengineering & translational medicine · 2025Article
- Metabolic engineering of Lactobacilli spp. for disease treatment.Microbial cell factories · 2025Review
- Bioactive Ingredients from Dairy-Based Lactic Acid Bacterial Fermentations for Functional Food Production and Their Health Effects.Nutrients · 2023Review
- Genetically engineered Lactobacillus paracasei rescues colonic angiotensin converting enzyme 2 (ACE2) and attenuates hypertension in female Ace2 knock out rats.Pharmacological research · 2023Article
- Probing the functional and therapeutic properties of postbiotics in relation to their industrial application.Food science & nutrition · 2023Review
- The Gut-Heart Axis: Updated Review for The Roles of Microbiome in Cardiovascular Health.Korean circulation journal · 2023Review
- Modes of therapeutic delivery in synthetic microbiology.Trends in microbiology · 2023Review
- Article
- Current and future methods of probiotic therapy for necrotizing enterocolitis.Frontiers in pediatrics · 2023Review
- Long-term use of probiotics for the management of office and ambulatory blood pressure: A systematic review and meta-analysis of randomized, controlled trials.Food science & nutrition · 2023Review
- Regulatory effect of gut microbes on blood pressure.Animal models and experimental medicine · 2022Review
- Host-microbial interactions in metabolic diseases: from diet to immunity.Journal of microbiology (Seoul, Korea) · 2022Review
- Bioactive peptides produced by engineered probiotics and other food-grade bacteria: A review.Food chemistry: X · 2022Article
- Article
- Article
- Genetically engineered bacterium: Principles, practices, and prospects.Frontiers in microbiology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHypertension is considered the most serious risk factor for cardiovascular disease. Angiotensin-converting enzyme inhibitory peptides (ACEIPs), which are made from tuna frame protein (TFP) and yellow fin sole frame protein (YFP), have been used previously to treat hypertension. However, the production of these short peptides is usually dependent on enzymatic hydrolysis, resulting in a digested mixture that makes it difficult to purify the ACEIPs. Although it has been reported that ACEIPs could be produced in recombinant Escherichia coli strains, the use of lactic acid bacteria in the production of ACEIPs has not been demonstrated.
resultsIn this study, the ACEIP coding sequences from TFP and YFP were joined through an arginine linker and expressed in the Lactobacillus plantarum (Lb. plantarum) NC8 strain by an inducible vector pSIP-409. Then, the antihypertensive effects were determined in the model of spontaneously hypertensive rats (SHRs) by measuring the blood pressure, hematology, blood biochemistry and nitric oxide (NO), endothelin (ET) and angiotensin II (Ang II) levels. The results showed that oral administration of recombinant Lb. plantarum NC8 (RLP) significantly decreased systolic blood pressure (P < 0.01) during treatment, which lasted for at least 10 days after the last dose. Furthermore, the presence of RLP resulted in an increased level of NO, as well as decreased levels of ET and Ang II in plasma, heart, and kidney. In addition, a dramatically decreased triglyceride level was also observed even though there was no significant change in hematology or blood biochemistry. Although some drawbacks were still observed, such as the presence of an antibiotic selection marker, no obvious side effects or bacterial translocation were observed in vivo, indicating the potential application of RLP in the treatment of hypertension.
conclusionThese results demonstrated the effectiveness and safety of RLP on the treatment of hypertension.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.